174 related articles for article (PubMed ID: 19361841)
1. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom.
Arellano FM; Arana A; Wentworth CE; Fernández-Vidaurre C; Schlienger RG; Conde E
J Allergy Clin Immunol; 2009 May; 123(5):1111-6, 116.e1-13. PubMed ID: 19361841
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Siegfried EC; Jaworski JC; Kaiser JD; Hebert AA
BMC Pediatr; 2016 Jun; 16():75. PubMed ID: 27267134
[TBL] [Abstract][Full Text] [Related]
3. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Arellano FM; Wentworth CE; Arana A; Fernández C; Paul CF
J Invest Dermatol; 2007 Apr; 127(4):808-16. PubMed ID: 17096020
[TBL] [Abstract][Full Text] [Related]
4. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
5. Potent topical steroids are one of the treatments for cutaneous T-cell lymphoma.
Fernandez-Peñas P
J Allergy Clin Immunol; 2010 Aug; 126(2):414; author reply 414-5. PubMed ID: 20621338
[No Abstract] [Full Text] [Related]
6. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
7. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
8. Retrospective markers of paediatric atopic dermatitis persistence after hospital diagnosis: A nationwide cohort study.
Thyssen JP; Corn G; Wohlfahrt J; Melbye M; Bager P
Clin Exp Allergy; 2019 Nov; 49(11):1455-1463. PubMed ID: 31464039
[TBL] [Abstract][Full Text] [Related]
9. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns.
Horii KA; Simon SD; Liu DY; Sharma V
Pediatrics; 2007 Sep; 120(3):e527-34. PubMed ID: 17766497
[TBL] [Abstract][Full Text] [Related]
10. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Legendre L; Barnetche T; Mazereeuw-Hautier J; Meyer N; Murrell D; Paul C
J Am Acad Dermatol; 2015 Jun; 72(6):992-1002. PubMed ID: 25840730
[TBL] [Abstract][Full Text] [Related]
11. Trends in Atopic Dermatitis Management: Comparison of 1990-1997 to 2003-2012.
He A; Feldman SR; Fleischer AB
J Drugs Dermatol; 2018 Feb; 17(2):135-140. PubMed ID: 29462220
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
13. Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial.
van Halewijn KF; Bohnen AM; van den Berg PJ; Pasmans SGMA; Bindels PJE; Elshout G
BMJ Open; 2019 Jun; 9(6):e027239. PubMed ID: 31221882
[TBL] [Abstract][Full Text] [Related]
14. Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study.
Huang HH; Shen D; Chan TC; Cho YT; Tang CH; Chu CY
Am J Clin Dermatol; 2023 Sep; 24(5):799-808. PubMed ID: 37280416
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with steroid phobia in caregivers of children with atopic dermatitis.
Kojima R; Fujiwara T; Matsuda A; Narita M; Matsubara O; Nonoyama S; Ohya Y; Saito H; Matsumoto K
Pediatr Dermatol; 2013; 30(1):29-35. PubMed ID: 22747965
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic, prophylactic and therapeutic guidelines in patients with atopic dermatitis. Position paper by the task force of the National Specialists on Dermatology, Venereology and Allergology].
Gliński W; Kruszewski J; Silny W; Kurzawa R; Czarnecka-Operacz M; Baran E; Szepietowski J;
Pol Merkur Lekarski; 2004; 17 Suppl 3():3-15. PubMed ID: 15688665
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.
Tennis P; Gelfand JM; Rothman KJ
Br J Dermatol; 2011 Sep; 165(3):465-73. PubMed ID: 21466537
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outpatient Prescription Patterns for Atopic Dermatitis in the United States.
Singh P; Silverberg J
Dermatitis; 2019; 30(5):294-299. PubMed ID: 31524757
[TBL] [Abstract][Full Text] [Related]
19. An innovative oat-based sterile emollient cream in the maintenance therapy of childhood atopic dermatitis.
Mengeaud V; Phulpin C; Bacquey A; Boralevi F; Schmitt AM; Taieb A
Pediatr Dermatol; 2015; 32(2):208-15. PubMed ID: 25529232
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, incidence and management of atopic dermatitis in Australian general practice using routinely collected data from MedicineInsight.
Chidwick K; Busingye D; Pollack A; Osman R; Yoo J; Blogg S; Rubel D; Smith S
Australas J Dermatol; 2020 Aug; 61(3):e319-e327. PubMed ID: 32173859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
